Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)

An open label study to assess the safety, tolerability, and effects of intranasal ketamine in combination with rTMS for patients with treatment-resistant major depressive disorder (TRD). Patients will be given a dose of ketamine followed by 6 weeks of rTMS treatment.

Topic Depression
Compound Ketamine
Country United States of America
Visit trial
Status Not yet recruiting
Results Published
Start date 05 January 2020
End date 05 January 2022
Phase Phase IV
Design Open
Type Interventional
Generation First
Participants 20
Sex All
Age 18- 65
Therapy No

Trial Details

Investigate the effects of pretreatment using a single, sub-anesthetic dose of intranasal ketamine on the response to a standard course of rTMS in patients who meet the definition of TRD.

Trial Number NCT04352621

Sponsors & Collaborators

University of Cincinnati
This company doesn't have a full profile yet, it is linked to a clinical trial.

Measures Used

Quick Inventory of Depressive Symptomatology
The Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR16) is a self-report tool designed to screen for depression and measure changes in the severity of symptoms.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.